Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Post by paljoeyon Aug 30, 2012 7:29am
225 Views
Post# 20278036

US GDP accelerating

US GDP accelerating

WASHINGTON (MarketWatch) — The U.S. economy expanded somewhat faster in the second quarter than originally reported because of higher consumer spending and slower growth in imports, the government said Wednesday.

Gross domestic product increased at a 1.7% rate in the April-to-June period, up from a first read of 1.5%, the Commerce Department said. GDP — the value of all goods and services produced in the U.S. — is the broadest measure of an economy’s health.

The economy’s current level of growth, however, still falls well short of what’s needed to dramatically lower the nation’s high unemployment rate and eliminate the lingering threat of another recession.

The U.S. has grown at below-average rates since exiting the last recession in mid-2009, held back mainly by poor job growth. The nation’s unemployment rate has hovered above 8% for 42 straight months, marking the longest period of prolonged labor-market weakness since the Great Depression.

 

Nor do economists expect growth to accelerate much in the near future. The U.S. is projected to grow 2.0% in the third quarter and 1.9% in the final three months of the year. Soft consumer spending, weakness in the global economy and the threat of higher U.S. taxes and deep spending cuts next year are among the headwinds restraining growth, analysts say.

 

Bullboard Posts